Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing lo

Equities researchers at BMO Capital Markets initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Friday, PriceTargets.com reports. The brokerage set an outperform rating and a $780.00 price target on the biopharmaceutical companys stock. BMO Capital Markets price target indicates a potential upside of 19.51% from the stocks current price. Several []

SOA Wealth Advisors LLC. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 152 shares of the biopharmaceutical companys stock after acquiring an additional 30 shares during the period. SOA Wealth Advisors LLC.s []

SOA Wealth Advisors LLC. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.6% during the third quarter, HoldingsChannel.com reports. The fund owned 152 shares of the biopharmaceutical companys stock after purchasing an additional 30 shares during the quarter. SOA Wealth Advisors LLC.s holdings in Regeneron Pharmaceuticals were worth $91,000 as of its []

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CFO Robert E. Landry sold 681 shares of the businesss stock in a transaction dated Wednesday, November 17th. The shares were sold at an average price of $645.08, for a total transaction of $439,299.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC []

The therapy will likely face stiff competition from more convenient COVID-19 pills.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director George L. Sing sold 6,000 shares of the businesss stock in a transaction dated Tuesday, November 16th. The stock was sold at an average price of $656.26, for a total transaction of $3,937,560.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC []

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Andrew J. Murphy sold 7,167 shares of the businesss stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $647.17, for a total value of $4,638,267.39. The transaction was disclosed in a legal filing with the SEC, which is available at []

Veriti Management LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,662 shares of the biopharmaceutical companys stock after acquiring an additional 237 shares during the quarter. Veriti Management LLCs holdings in Regeneron []

TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.

Related Stocks: TWTR , TMO , SRPT , EA , GM , MSFT , IBM , ATVI , WLTW , JAZZ , JNPR , DTM , MU , FIVN , REGN , CSCO , BABA , NFLX ,

Related Stocks: BMY , NVDA , FB , WMT , DIS , PFE , ASML , MU , C , REGN ,

The European Commission (EC) has approved New York-based biotechnology company Regeneron Pharmaceuticals, Inc.s (REGN) casirivimab and imdevimab antibody cocktail for people aged at The post Regeneron Gets EU Approval for COVID-19 Antibody Cocktail, Announces $3B Share Repurchase Program appeared first on Smarter Analyst .

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

Nasal Polyps Diagnosis and Treatment Market Scenario 2020-2027: The Global Nasal Polyps Diagnosis and Treatment market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2027. On the basis of historical data, Nasal Polyps Diagnosis and Treatment market report provides key segments and their sub-segments, revenue and []